pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
AdCom · news · pharmadog
← back to AdCom
News · AdCom
169
stories
15h
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
biospace
4d
FDA’s device center releases guidance agenda for FY 2027
raps
4d
This Week at FDA: No Overton vote until after midterms, FDA signals advisory committee support, and more
raps
5d
FDA Launches Nationwide Effort to Expand Scientific Expertise and Consumer Voices to Advisory Committees
fda press
6d
FDA call for new adcomm members signals renewed interest in outside advisors
raps
7d
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
11d
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
biospace
11d
Trump's FDA pick Heidi Overton calls vaccines, mifepristone safe and effective in confirmation hearing
fiercebiotech
12d
Grail survives adcomm vote as it awaits FDA decision for cancer blood test
fiercebiotech
12d
Recon: Adcomm backs Grail’s cancer test; Lilly, China’s InnoCare sign $3.35B deal
raps
12d
STAT+: FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks
stat
12d
FDA adcomm votes in favor of benefit-risk of Grail’s cancer test
endpoints
13d
Compass vows to press on with FDA application despite new trial request
biospace
13d
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
stat
14d
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
stat
14d
FDA offers little comment on Grail cancer test ahead of adcomm
endpoints
15d
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
15d
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
biospace
15d
Recon: FDA staff raise no major concerns for Grail multi-cancer test ahead of adcomm; Trump admin drafting order to exert contro...
raps
18d
Kennedy announces new effort to speed up autism diagnoses
stat
18d
ARPA-H launches SPECTRA program, new autism research initiative
fiercebiotech
21d
AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market
biospace
21d
Pennsylvania records third measles-related death amid outbreak
stat
22d
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
25d
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
fiercebiotech
27d
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
biopharma dive
27d
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
biospace
27d
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
28d
Recon: FDA approves AZ’s breast cancer drug over negative adcomm vote; Novartis sees setbacks for drugs targeting cholesterol, m...
raps
28d
FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote
endpoints
← prev
page 1 of 6
next →
